



Childhood diabetes

Dr.Sarah Mathai
Paediatric Endocrinologist
Child Health unit1, CMCH

True stories from our Department

		7yrs, boy	2.5 yrs, girl	4 yrs, girl	10 yrs, boy	15 yr, girl
Symptoms		Low grade fever, cough X 2 days Fast breathing X 7 hours	Excessive thirst, lethargy, urinary urgency & increased frequency X 1 week	Irritability, fast breathing X 4 hours Direct questioning, nocturia, weight loss X 2 weeks	Injury to L toe x 2 weeks GP checked RBS for non-healing, RBS at 3 pm 350, referred to CMCH	Breathing difficulty, altered sensorium 15 kg weight loss over 1 month
Findings		Moderately dehydrated Markedly acidotic Chest clear	Not dehydrated, very lethargic, not acidotic, systems N	Moderately dehydrated Acidotic No focus of infection	Appears well, but wasted Wound L toe	Markedly acidotic, comatose
Lab	RBS	756	435	648	550	1230
	Urine ketones	4+	3+	3+	2+	3+
	ABG	pH 6.9 ABE - unrecordable	pH 7.4 HCO3 : 22	pH 7.2 HCO3 : 5	pH 7.4 HCO3: 18	pH 6.8 HCO3 < 5


Introduction

- ✚ Clinical condition resulting from absolute or relative insulin deficiency
- ✚ Characterized by abnormalities in the metabolism of carbohydrate, protein and lipids



Pancreas – functional anatomy of endocrine portion

- ▶ Insulin produced by the β cells in the islets of Langerhans
- ▶ Islets make up 2% of the volume of pancreas, 80% by the exocrine portion of the pancreas



Classification

- ▶ **Type 1 diabetes**

Absolute insulin def resulting from progressive β cell destruction

1. immune mediated
2. idiopathic

- ▶ **Type 2 diabetes**

Relative insulin def with insulin resistance

- ▶ **Secondary diabetes**



Secondary diabetes

- Genetic defects in β cell function
 1. MODY (1–6)
 2. mitochondrial diabetes


- Genetic defects in insulin action
 1. Type A insulin resistance
 2. leprechaunism
 3. Rabson–Mendenhall syndrome
 4. Lipoatrophic diabetes



Secondary diabetes contd—

- **Diseases of the exocrine pancreas**
 1. Cystic fibrosis
 2. Pancreatitis
 3. Haemochromatosis
 4. Neoplasm etc

- **Endocrinopathies**
 1. Cushing syndrome
 2. Thyrotoxicosis
 3. Pheochromocytoma etc



Secondary diabetes contd—

- **Drugs**

glucocorticoids , thiazides
diazoxide, dilantin, pentamidine etc

- **Infections**

congenital rubella
CMV

- **Syndrome related**

Turner, Klinefelter, Down
Prader Willi , Lawrence–Moon–Biedl etc



Type I diabetes

- ▶ Commonest type in children

- Incidence varies :

Finland : 40/yr/100,000

Japan : 1/yr/100,000

S.India : 10.5/yr 100,000

(Ramachandran A, 1996)

- Alarming rate of increase in incidence worldwide compared to 1997, 40% higher incidence expected by 2010




- ▶ Severe insulin def– exogenous insulin absolutely essential to prevent ketosis and death
- ▶ Peak incidence
 1. at 5–7 yrs : ? Infection exposure at school entry
 2. during puberty : ? Insulin anatagonising effects of pubertal hormones(gonadal steroids, GH)
- ▶ No gender difference, no socioeconomic bias



Steps in pathogenesis

- ▶ Genetic predisposition (HLA region)
- ▶ Environmental trigger
(viruses, dietary agents, toxins & stress)
- ▶ Initiation of autoimmunity
against insulin, islet cell, GAD
(ICA, GAD, IAA)
- ▶ Prediabetic phase of progressive islet cell
destruction
- ▶ Clinical onset of diabetes
(when > 90% of pancreas cells get destroyed)





Adapted from Atkinson MA et al, Lancet 2001;358:221-229

How do we maintain euglycaemia?

- Normal plasma glucose

Interplay between Insulin & Glucagon
(also other counter regulatory hormones like cortisol, GH, adrenaline)

- Insulin – most important anabolic hormone

During fasting: Low insulin levels result in catabolism and mobilisation of stored energy

Postprandial: High insulin levels result in an anabolic state, with excess energy stored as fuel for future use



Some terminologies

- ▶ Glycogenesis : glycogen synthesis from glucose
- ▶ Glycolysis : breakdown of glycogen to release glucose
- ▶ Gluconeogenesis : glucose synthesis from non-CHO substrates like amino acids, lactate etc
- ▶ Lipogenesis : synthesis of lipids
- ▶ Lipolysis : breakdown of lipids to fatty acids & glycerol



Main sites of insulin action

Skeletal muscle

1. stimulates glucose uptake
glycogen synthesis
glycolysis
2. stimulates aa uptake & protein synthesis

Adipose tissue

1. stimulates glucose uptake & storage as TG
2. inhibits lipolysis

Liver

1. Promotes glycogenesis & suppresses glycolysis
2. suppression of gluconeogenesis
3. stores FA as TG

What are the anabolic effects of Insulin?

Glucose

1. promotes utilisation as energy source
2. promotes storage as glycogen for future fuel
3. Inhibits glycogen breakdown in liver
4. Inhibits gluconeogenesis

Aminoacids

1. Stimulates protein synthesis

Lipids

1. Enhances fat storage
2. Prevents mobilisation of fat as energy

T1 diabetes is a progressive catabolic state due to insulin deficiency



Effects of insulin deficiency

All symptoms are due to effects on

- ▶ Carbohydrate Metabolism
- ▶ Protein Metabolism
- ▶ Lipid Metabolism



Consequences on CHO metabolism

- ▶ Hyperglycaemia exceeding renal threshold



- ▶ Glucose leak in urine (glucosuria)



- ▶ Osmotic diuresis (polyuria, nocturia), loss of electrolytes in urine




- ▶ Dehydration and increased thirst (polydypsia)

- ▶ To maintain energy balance, increased food intake (polyphagia)



Consequences on lipid metabolism

- ▶ Increased lipolysis and decreased lipid synthesis



- ▶ Loss of adipose tissue

- ▶ Unsuppressed lipolysis with excessive FFA production → increased Acetyl CoA



- ▶ Elevated plasma and urine ketones



Consequences on protein metabolism

- ▶ Increased protein breakdown & decreased synthesis



- ▶ Muscle wasting



Role of counterregulatory hormones

- ▶ Insulin deficiency



- ▶ Wasting, dehydration, loss of electrolytes
(physiologic stress state)



- Hypersecretion of counterregulatory hormones




- Metabolic decompensation




Pathophysiology of DKA

Insulin def + Excess counterregulatory hormones

- 
- ```
graph TD; A[Insulin def + Excess counterregulatory hormones] --> B[Accelerated lipolysis → Increased FFA]; B --> C[Accumulation of ketone bodies(acetone, acetoacetate, βhydroxybutyrate)]; C --> D[Metabolic acidosis, compensatory Kussmaul's breathing]; D --> E[Progressive dehydration, acidosis, hyperosmolarity → coma & death (if untreated)];
```
- ▶ Accelerated lipolysis → Increased FFA
  - ▶ Accumulation of ketone bodies( acetone, acetoacetate,  $\beta$ hydroxybutyrate)
  - ▶ Metabolic acidosis, compensatory Kussmaul's breathing
  - ▶ Progressive dehydration, acidosis, hyperosmolarity → coma & death (if untreated)

# Clinical features

- **Of hyperglycaemia:** Polyuria, polydypsia, polyphagia, nocturia, weight loss & weakness
- **+ Ketosis** : abdominal discomfort, nausea, vomiting  
progressive & rapid deterioration
- **Diabetic ketoacidosis : moderate to severe**  
dehydration, acidotic breathing, fruity odour of the breath  
shock, cerebral obtundation & death if left untreated



# Diagnosis



## ✚ Plasma sugar (mg%)

|                     | Normal | Impaired | DM         |
|---------------------|--------|----------|------------|
| Fasting             | <110   | 111–125  | $\geq 126$ |
| 2hr post<br>glucose | <140   | 141–199  | $\geq 200$ |

OR

## ✚ Any random blood sugar $\geq 200$ mg% with the classic symptoms

*American Diabetes Association criteria, Diabetes care, 1999*

# Other investigations

- Baseline HbA1C (at diagnosis)
  - duration of hyperglycaemia
  - to evaluate treatment efficacy over time
- Autoantibodies to  $\beta$  cell
  - not essential in non-obese children
- Other autoantibodies
  - coeliac disease (TTG IgA)
  - thyroid (TPO, TG)
- TSH, TFT
  - few weeks after stabilisation



# Management

**Needs a multidisciplinary team :**

paediatrician/paediatric endocrinologist,  
diabetes nurse educator, dietitian,  
social worker, psychologist

## Goals

- Adequate glycaemic control while avoiding hypoglycaemia
- Permit normal growth & development with minimal effect on lifestyle
- Prevent ketoacidosis





# Principles of management

- Insulin therapy
- Balanced diet
- Regular exercise
- Regular monitoring




# Insulin therapy

- ▶ Forms the cornerstone of management of Type1 DM
- ▶ Initiation at 0.7 unit/kg/day for pre-pubertal children, 1–1.5 units/kg/day during puberty
- ▶ Injection at least twice a day (2–4 times/ day)



# Physiological insulin secretion



(intermediate-acting insulins, long-acting insulin analogs)

**Ultimate goal of insulin therapy**


**- to mimic endogenous insulin secretion**

# Commonly used insulins

Classification on the basis of their peak effect and duration of action:

- Short acting: Regular insulin
- Intermediate acting: NPH/ Lente
- Long acting : Ultralente
- Premixed:(30/70), (50/50) – **not recommended in children**

## Insulin analogs


- Short acting : Lispro /Aspart
  - Long acting : Glargine
- 

# Physiologic prandial response

## Intraportal, biphasic & rapid

### Regular insulin

- ▶ an initial lag phase
- ▶ plasma insulin level peaks after 1 to 2 hrs
- ▶ returns to basal levels after ~ 6 to 8 hrs



### Insulin analogs –lispro and aspart

- ▶ faster onset (5–10 min)
- ▶ shorter duration of action
- ▶ more closely resemble endogenous insulin secretion
- ▶ particular importance among infants and preschool-aged children, whose food intake may be inconsistent

# Basal insulins

## NPH/ULtralente


reduced solubility at physiologic pH –  
slower absorption

## Disadvantages

- considerable dose-to-dose variation
- not “peakless” – can cause nocturnal hypoglycemia

## Glargine/Detemir


- ▶ prolonged absorption
- ▶ more consistent diurnal release of insulin – no pronounced peak over 24 hours
- ▶ flatter & longer action profile
- ▶ Glargine: Inc IGF-1 receptor affinity ? Mitogenic potency





# Insulin action profile

| <b>Insulin</b>    | <b>Onset</b>   | <b>Peak</b>    | <b>Duration</b>  |
|-------------------|----------------|----------------|------------------|
| <b>Regular</b>    | <b>30min</b>   | <b>2-4hrs</b>  | <b>6-8 hrs</b>   |
| <b>NPH</b>        | <b>2-4hrs.</b> | <b>5-7 hrs</b> | <b>12-16 hrs</b> |
| <b>Lente</b>      | <b>2-4hrs.</b> | <b>6-8 hrs</b> | <b>12-18 hrs</b> |
| <b>Ultralente</b> | <b>6-12hrs</b> | <b>No Peak</b> | <b>18-30 hrs</b> |



# Insulin regime

## Split-mix

- combination of an intermediate acting with a short acting insulin given twice a day
- Lispro preferred in toddlers with erratic food intake
- pre-BF :  $\frac{2}{3}^{\text{rd}}$  total dose of insulin  
                     $\frac{2}{3}$  intermediate acting  
                     $\frac{1}{3}$  short acting  
pre-dinner :  $\frac{1}{3}^{\text{rd}}$  total dose of insulin

# Insulin regime

## Basal-bolus regime

- using single dose Glargine in the evening with twice or thrice a day short acting
- particularly useful in children with risk of nocturnal hypoglycaemia



# Insulin therapy

- Proper storage
- Strength of insulin & syringe(U 40/ U100)
- Correct sequence of insulin in the syringe–regular followed by intermediate acting
- Roll syringe gently to warm insulin (to bring it to room temp)
- Correct technique of administration (45 deg subcut) & regular rotation of the sites

# Insulin injection sites



Insulin injection sites:

- Outer arm
- Abdomen
- Hip area
- Thigh

# A case scenario

- ▶ 6yrs old, newly diagnosed Type 1 diabetic child (hyperglycaemia, ketonuria, no acidosis)
- ▶ Weight 18 kg
- ▶ Commence on
  - pre-BF Insulotard 6
  - Actrapid 4
  - pre-dinner Insulotard 3
  - Actrapid 2



# Insulin dose adjustment– an example


Pre-BF - Insulotard 6  
Actrapid 4

Pre-dinner – Insulotard 3  
Actrapid 2

| Date     | Pre-BF | 2hrPC | Pre-lunch | Pre-dinner | Bed-time |
|----------|--------|-------|-----------|------------|----------|
| 29/06/09 | 212    | 280   | 200       | 225        | 130      |

# Diet

- ▶ To maintain ideal body wt and promote growth
- ▶ 3 main meals (BF, lunch & dinner) and 3 midmeal snacks
- ▶ Split up of calories
  - CHO : 50–65%
  - proteins : 10–20%
  - fats : 25–30%
- Carbohydrate counting (carb count)






# Diet

- Main restriction is for highly refined sugars or foods with high glycaemic index
- ▶ Family pot feeding, food exchange lists with glycemic index
- ▶ Special treats



# Exercise/physical activity

**Children should be encouraged to participate in all games and sports activities**

- ▶ Stimulates glucose uptake into the skeletal muscle
  - ▶ Plays a very important role in the management of diabetes
  - ▶ Risk of hypoglycaemia with vigorous exercise– add on an extra carb exchange before and after exercise / reduction of insulin dose by 10–15% on that day
- 

# Another important guideline

- ▶ 3 year old, diagnosed as T1 diabetes a year ago. Has developed fever, cough and post tussive vomiting. How will you advise the mother?



# Sick day issues

- ▶ Aims

- Prevent dehydration

- Prevent ketoacidosis

- Prevent hypoglycaemia

Ketonemia/ketonuria suggests

- a. either insulin deficiency

- stress hormones, inadequate insulin doses, missed insulin doses

- b. or Low glucose levels due to fasting or starvation

- eg. Acute gastroenteritis



# Sick day guidelines

**Any infection in a diabetic child can precipitate DKA**

- Maintain hydration
- Frequent blood glucose monitoring at home
- Check for urine ketones– if positive , will need more short acting insulin and careful monitoring till ketonuria clears
- Hospitalisation if ketonuria/hyperglycaemia persists or child develops persistent vomiting



# Monitoring

## Home blood glucose monitoring(HBGM)

- ideally  $\geq 4$  times a day
- in our set-up, monitoring for 3 days at least twice a month (pre-BF, pre-lunch, pre-dinner, bedtime)
- midnight & 3 am monitoring for nocturnal hypoglycaemia (CGMS ideal)

## During follow-up

- Growth and pubertal assessment
- Glycosylated Hb (HbA1C)
- BP, Injection sites

## Screening for complications



# Complications

- ▶ Diabetic ketoacidosis
- ▶ Hypoglycemia
- ▶ Impact on growth and puberty



# Complications

- ▶ Long term complications due to uncontrolled diabetes

Nephropathy

Retinopathy

annually after 5 yrs of onset in  
pre-pubertal children, after 2 yrs of onset in  
pubertal children

Neuropathy

Limited joint mobility





# Associated autoimmune conditions

- ▶ Thyroiditis
- ▶ Coeliac disease
- ▶ Addison's disease



# Honeymoon period

- ▶ Most children have partial remission following the diagnosis
- ▶ Transient improvement in  $\beta$  cell fn
- ▶ Insulin dose  $< 0.5$  u/kg
- ▶ Duration – few months from diagnosis upto 2 years
- ▶ Maintain low dose insulin treatment even during the honeymoon period



(Newer) techniques  
(not yet used in children with Type 1 diabetes  
in our unit)



## Other modalities of insulin administration



- ▶ As nasal spray
- ▶ Follow-up studies upto 10 weeks and 6 months in adults promising
- ▶ Trial on in children & adolescents
- ▶ Long term efficacy & safety not known

CSII

Inhaled insulin

# Monitoring devices

- ▶ Continuous blood glucose monitoring (CBGM)
  - ▶ measures interstitial blood glucose via an indwelling cannula in the abdomen/buttocks
  - ▶ expensive
- ▶ Non-invasive blood glucose monitoring
  - ▶ reverse iontophoresis
  - ▶ Device worn like a wristwatch approved for patients > 7 years in the US
  - ▶ expensive



## Miniglucagon therapy

- ▶ For home based management of hypoglycaemia especially during sick days
- ▶ Avoids need for hospitalisation to a large extent



# Increasingly prevalent scenario

- ▶ 14 yr old boy
- ▶ Foul smelling urine X 2 months
- ▶ Nocturia X 3 weeks
- ▶ Some lethargy
- ▶ O/E : Wt > 97<sup>th</sup> percentile  
BMI 27 kg/m<sup>2</sup>  
Acanthosis nigricans  
Not dehydrated or acidotic



## What investigations would you like to do?

- Random blood glucose : 385  
If inconclusive, Fasting & 2 hr  
postprandial blood glucose
- Urine ketones  
negative
- Arterial blood gas  
not done because urine ketones neg
- Type 1 diabetes autoantibodies  
especially if ketonuria



Most recent advance in insulin?



# Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus

*Sarita et al, National Academy of Sciences, July 2010*

- ▶ “Administration of a single dose of the insulin oligomer(supramolecular insulin assembly II (SIA-II)), to experimental diabetic animals released insulin capable of maintaining physiologic glucose levels for > 120 days for bovine and > 140 days for recombinant human insulin without fasting hypoglycemia
- ▶ The novel SIA-II not only improved the glycemic control, but also reduced the extent of secondary diabetic complications”
- ▶ *Adapted version of the abstract*

